Copley Scientific to present at the Generic Respiratory Drug Development Symposium in Mumbai, India
Mark Copley, Sales Director at Copley Scientific, will be presenting as one of the industry experts at the two-day Generic Respiratory Drug Development Symposium.
- (1888PressRelease) January 10, 2017 - Nottingham, UK: Mr Copley is presenting on the topic of "Improving the clinical relevance of in vitro testing methods for orally inhaled products (OIPs)". The symposium is due to take place from 19th - 20th January 2017 at Hotel Meluha The Fern, Mumbai, India (http://allianceindia.co.in/index.php/events/readmore/GENERIC-RESPIRATORY-DRUG-DEVELOPMENT-SYMPOSIUM).
This inaugural conference brings together the generic respiratory drugs community to discuss advances relating to generic inhalation and nasal spray drugs; an area experiencing continued growth as blockbuster inhalation products come off patent. Presentations at the event cover a wide range of topics, including analytical method development, Quality by Design (QbD) approaches, regulatory requirements and manufacturing challenges.
"In-vitro test methods are widely used to assess the performance of generic OIP drug delivery, to ensure product consistency and to support claims of bioequivalence" explains Mr Copley. "Understanding and improving the clinical relevance of these methods is an important issue for the industry and Copley Scientific is delighted to have been invited to present at the Generic Respiratory Drug Development Symposium on this topic. Indian based pharmaceutical companies are highly active within this sector and I am looking forward to interacting with key executives in global R&D, product development, drug discovery, regulatory and manufacturing roles."
Alongside Mark Copley, speakers include Dr Gur Jai Pal Singh (Head - Cipla Respiratory Center of Excellence) and Dr Guirag Poochikian (President - Poochikian Consulting and former US FDA Associate Director for Regulatory Science). Find out more online at www.copleyscientific.com
About Copley Scientific
Copley Scientific is recognised as the world's leading manufacturer and supplier of inhaler test equipment and is a major provider of testing systems for other pharmaceutical dosage forms. The company is also active in detergent testing, air sampling and aerosol characterisation.
Copley Scientific's pharmaceutical product range includes test equipment for: delivered dose uniformity and aerodynamic particle size measurement of metered-dose inhalers, dry powder inhalers, nebulizers and nasal sprays; as well as tablets (dissolution, disintegration, friability and hardness) capsules, powders, suppositories and transdermals.
Copley Scientific has offices in the UK and Switzerland. The company works in partnership with aerosol particle science experts MSP Corporation in North America, and also distributes MSP Corporation's air sampling and aerosol characterisation products throughout Europe.
Serving the pharmaceutical and associated industries, Copley Scientific offers an extensive range of equipment for research, development and quality control, as well as full validation and aftersales services. This broad range of products is supplied and supported worldwide through a network of specialist distributors. www.copleyscientific.com
For further information
Press information
Trystan George, Kapler Communications
1 Whiteside, Station Road, Holmes Chapel, Cheshire, CW4 8AA, UK
Tel: +44 (0) 1477 539 545; Fax: +44 (0) 1477 539 540
copley ( @ ) kapleronline dot com
Company contact:
Mark Copley, Sales Director, Copley Scientific Limited
Colwick Quays Business Park, Private Road No. 2, Colwick, Nottingham
UK NG4 2JY
Tel: +44 (0)115 961 6229; Fax: +44 (0)115 961 7637
m.copley ( @ ) copleyscientific dot co dot uk
www.copleyscientific.com
European Office (Austria, France, Germany, Italy, Switzerland)
Copley Scientific AG
Erlenstrasse 27, Postfach 152, CH-4106 Therwil, Switzerland
Tel: +41 (0)61 725 25 35; Fax: +41 (0)61 721 31 87
sales ( @ ) copleyscientific dot ch
www.copleyscientific.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam